Please assess the completion status of the following clinical trial:

Trial Title: Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \>= 20 years at informed consent.~2. Patients who have provided written informed consent themselves.~3. Patients who have metastatic and/or advanced lesion~4. Documentation of ER-positive and/or PR-positive tumor (\>=1% positive stained cells).~5. Patients with cancer confirmed to be HER2-negative.~6. Patients with confirmed menopause~7. Patients who have plans of 2nd hormone therapy.~8. Patients with a measurable lesion based on RECIST 1.1~9. Patients with ECOG PS of 0 to 1.~10. Patients without any severe disorder in the major organs.~Exclusion Criteria:~-~Exclusion Criteria:~1. Active or prior documented autoimmune disease within the past 2 years.~2. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab~3. Patients with central nervous system metastasis~4. Patients with life-threatening disease.~5. Patients with a history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody drug.~6. Patients who have received live vaccination within 30 days before start of the investigational products.~7. Patients with a past medical history of pneumonia requiring steroid treatment or with a past medical history of interstitial pneumonia.~8. Patients considered ineligible for participation in this study by their attending physicians.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Durvalmab&Tremelimumab&Fulvestrant (Type: EXPERIMENTAL): Durvalmab\&Tremelimumab\&Fulvestrant

Based on this trial design, predict the completion outcome and termination type (if applicable).